Factors Associated With Off-Label Use of Drug-Eluting Stents in Patients With ST-Elevation Myocardial Infarction
- 1 February 2008
- journal article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 101 (3) , 286-292
- https://doi.org/10.1016/j.amjcard.2007.09.084
Abstract
No abstract availableKeywords
This publication has 29 references indexed in Scilit:
- Outcomes and Complications Associated With Off-Label and Untested Use of Drug-Eluting StentsJAMA, 2007
- Unanswered Questions — Drug-Eluting Stents and the Risk of Late ThrombosisNew England Journal of Medicine, 2007
- Stent Thrombosis Redux — The FDA PerspectiveNew England Journal of Medicine, 2007
- Drug-Eluting Coronary Stents — Promise and UncertaintyNew England Journal of Medicine, 2007
- Paclitaxel-Eluting versus Uncoated Stents in Primary Percutaneous Coronary InterventionNew England Journal of Medicine, 2006
- Sirolimus-Eluting versus Uncoated Stents in Acute Myocardial InfarctionNew England Journal of Medicine, 2006
- A Polymer-Based, Paclitaxel-Eluting Stent in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 2004
- Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary ArteryNew England Journal of Medicine, 2003
- A Paclitaxel-Eluting Stent for the Prevention of Coronary RestenosisNew England Journal of Medicine, 2003
- A Randomized Comparison of a Sirolimus-Eluting Stent with a Standard Stent for Coronary RevascularizationNew England Journal of Medicine, 2002